NASDAQ:VIGL - Nasdaq - US92673K1088 - Common Stock - Currency: USD
3.03
+0.14 (+4.84%)
The current stock price of VIGL is 3.03 USD. In the past month the price increased by 28.94%. In the past year, price decreased by -3.19%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. The company is headquartered in Watertown, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The company is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The firm is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
VIGIL NEUROSCIENCE INC
100 Forge Road, Suite 700
Watertown MASSACHUSETTS US
Employees: 64
Company Website: https://www.vigilneuro.com/
Investor Relations: http://investors.vigilneuro.com
Phone: 18572544445
The current stock price of VIGL is 3.03 USD. The price increased by 4.84% in the last trading session.
The exchange symbol of VIGIL NEUROSCIENCE INC is VIGL and it is listed on the Nasdaq exchange.
VIGL stock is listed on the Nasdaq exchange.
15 analysts have analysed VIGL and the average price target is 16.19 USD. This implies a price increase of 434.41% is expected in the next year compared to the current price of 3.03. Check the VIGIL NEUROSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VIGIL NEUROSCIENCE INC (VIGL) has a market capitalization of 123.87M USD. This makes VIGL a Micro Cap stock.
VIGIL NEUROSCIENCE INC (VIGL) currently has 64 employees.
VIGIL NEUROSCIENCE INC (VIGL) has a support level at 3.02. Check the full technical report for a detailed analysis of VIGL support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VIGL does not pay a dividend.
VIGIL NEUROSCIENCE INC (VIGL) will report earnings on 2025-03-20, after the market close.
VIGIL NEUROSCIENCE INC (VIGL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.06).
The outstanding short interest for VIGIL NEUROSCIENCE INC (VIGL) is 5.68% of its float. Check the ownership tab for more information on the VIGL short interest.
ChartMill assigns a technical rating of 5 / 10 to VIGL. When comparing the yearly performance of all stocks, VIGL is a bad performer in the overall market: 69.18% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to VIGL. VIGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months VIGL reported a non-GAAP Earnings per Share(EPS) of -2.06. The EPS decreased by -0.98% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -62.92% | ||
ROE | -93.28% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 85% to VIGL. The Buy consensus is the average rating of analysts ratings from 15 analysts.